Suanfarma Suanfarma

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Tome Biosciences.

    Client Virtual Booth

    TOME BIOSCIENCES

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Tome Biosciences
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    AOTC, Watertown, Massachusetts
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://tome.bio/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/tome-biosciences/about/
    Twitter
    Twitter
    https://twitter.com/tome_bio

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Genevant Sciences to Collaborate with Tome Biosciences to Develop Gene Editing Therapeutic for Rare Liver Disorder

    Details:

    Under the collaboration, Genevant will combine its proprietary LNP technology with Tome’s programmable genomic integration (PGI) technology to develop an in vivo gene editing treatment for an undisclosed rare monogenic liver disorder.


    Lead Product(s): Undisclosed

    Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed

    Highest Development Status: Discovery PlatformProduct Type: Cell and Gene therapy

    Recipient: Genevant Sciences

    Deal Size: $114.3 million Upfront Cash: Undisclosed

    Deal Type: Collaboration January 16, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Tome Biosciences Launches with Over $200 Million in Funding to Advance Programmable Genomic Integration Platform

    Details:

    The Company intends to use the net proceeds to develop integrative gene therapies for monogenic liver diseases and cell therapies for autoimmune diseases.


    Lead Product(s): Undisclosed

    Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed

    Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy

    Partner/Sponsor/Collaborator: Andreessen Horowitz

    Deal Size: $118.0 million Upfront Cash: Undisclosed

    Deal Type: Series B Financing December 12, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    fermion-oy-2024-05-13

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search